These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 12076065)

  • 1. Clinical aspects and management of cytomegalovirus infection.
    Sissons JG; Carmichael AJ
    J Infect; 2002 Feb; 44(2):78-83. PubMed ID: 12076065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytomegalovirus infection in immunocompetent and immunocompromised individuals--a review.
    Vancíková Z; Dvorák P
    Curr Drug Targets Immune Endocr Metabol Disord; 2001 Aug; 1(2):179-87. PubMed ID: 12476798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cytomegalovirus infection in pregnancy].
    Pusztai R
    Orv Hetil; 2009 May; 150(21):963-8. PubMed ID: 19443304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Is maternal infection with cytomegalovirus prevention possible?].
    Cordier AG; Vauloup-Fellous C; Picone O
    Gynecol Obstet Fertil; 2010 Oct; 38(10):620-3. PubMed ID: 20884272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prevention of cytomegalovirus in organ transplantation].
    Aguado JM
    Rev Clin Esp; 1996 Apr; 196(4):240-7. PubMed ID: 8701064
    [No Abstract]   [Full Text] [Related]  

  • 6. Antiviral strategies to combat cytomegalovirus infections in transplant recipients.
    Lischka P; Zimmermann H
    Curr Opin Pharmacol; 2008 Oct; 8(5):541-8. PubMed ID: 18662804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acquisition of human cytomegalovirus infection in infants via breast milk: natural immunization or cause for concern?
    Schleiss MR
    Rev Med Virol; 2006; 16(2):73-82. PubMed ID: 16287195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytomegalovirus infection and disease in the new era of immunosuppression following solid organ transplantation.
    Fisher RA
    Transpl Infect Dis; 2009 Jun; 11(3):195-202. PubMed ID: 19228345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Incidence, therapy and prevention of cytomegalovirus disease after bone marrow transplantation].
    Schuler U; Ehninger G
    Med Klin (Munich); 1992 Oct; 87 Suppl 1():30-8. PubMed ID: 1334220
    [No Abstract]   [Full Text] [Related]  

  • 10. Combination antiviral strategies in managing cytomegalovirus infection.
    Martin M
    Transplant Proc; 1994 Oct; 26(5 Suppl 1):28-30. PubMed ID: 7940973
    [No Abstract]   [Full Text] [Related]  

  • 11. [Infections in bone marrow transplantation].
    Villasís-Keever A; Mosqueda JL
    Rev Invest Clin; 2005; 57(2):381-6. PubMed ID: 16524081
    [No Abstract]   [Full Text] [Related]  

  • 12. Evaluation of cytomegalovirus DNAaemia versus pp65-antigenaemia cutoff for guiding preemptive therapy in transplant recipients: a randomized study.
    Gerna G; Baldanti F; Torsellini M; Minoli L; Viganò M; Oggionnis T; Rampino T; Castiglioni B; Goglio A; Colledan M; Mammana C; Nozza F; Daniele L;
    Antivir Ther; 2007; 12(1):63-72. PubMed ID: 17503749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Critical evaluation of agents used in the treatment and prevention of cytomegalovirus infection in immunocompromised patients.
    Meyers JD
    Transplant Proc; 1991 Jun; 23(3 Suppl 3):139-42, discussion 142-3. PubMed ID: 1648819
    [No Abstract]   [Full Text] [Related]  

  • 14. Cytomegalovirus prophylaxis strategies in high-risk transplantation.
    Snydman DR
    Transplant Proc; 1994 Oct; 26(5 Suppl 1):20-2. PubMed ID: 7940971
    [No Abstract]   [Full Text] [Related]  

  • 15. Dendritic cell vaccination in allogeneic stem cell recipients: induction of human cytomegalovirus (HCMV)-specific cytotoxic T lymphocyte responses even in patients receiving a transplant from an HCMV-seronegative donor.
    Grigoleit GU; Kapp M; Hebart H; Fick K; Beck R; Jahn G; Einsele H
    J Infect Dis; 2007 Sep; 196(5):699-704. PubMed ID: 17674311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preemptive versus prophylactic approaches in the management of cytomegalovirus disease in solid organ transplant recipients: what we know and what we do not know.
    Meylan PR; Pascual M
    Clin Infect Dis; 2006 Oct; 43(7):881-3. PubMed ID: 16941369
    [No Abstract]   [Full Text] [Related]  

  • 17. Monitoring transplant patients for human cytomegalovirus: Diagnostic update.
    Gerna G; Lilleri D
    Herpes; 2006 May; 13(1):4-11. PubMed ID: 16732996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical relevance of cytomegalovirus infection in patients with disorders of the immune system.
    Steininger C
    Clin Microbiol Infect; 2007 Oct; 13(10):953-63. PubMed ID: 17803749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defining an optimal regimen for cytomegalovirus prophylaxis in organ transplant recipients.
    Paya CV
    Transplant Proc; 1996 Dec; 28(6 Suppl 2):9-11. PubMed ID: 9037269
    [No Abstract]   [Full Text] [Related]  

  • 20. [Prophylaxis of cytomegalovirus infection in the transplant recipient].
    Aguado JM; Lumbreras C; Otero JR
    Med Clin (Barc); 1992 Oct; 99(11):430-4. PubMed ID: 1335103
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.